Abstracts tagged "Cost-Effectiveness"

Abstract Number: 2111 • ACR Convergence 2025
Cost-effectiveness Analysis of Biosimilar Denosumab for the Treatment of Women with Post-menopausal Osteoporosis in the United States: A Risk Based Analysis
Edward Li¹, Rebecca McTavish², Fatemeh Mirzayeh fashami², Sarah Kane² and Marion Schauf³, ¹Sandoz Inc., West Princeton, NJ, ²EVERSANA, Burlington, ON, Canada, ³Sandoz International GmbH, Holzkirchen, Bayern, Germany
Background/Purpose: Post-menopausal osteoporosis (PMO) significantly increases the risk of fractures in women, necessitating effective treatment strategies. The introduction of biosimilar denosumab offers the opportunity to…
Abstract Number: 1975 • ACR Convergence 2025
Baseline QTc Screening and Monitoring Among SARD Patients with High Cardiovascular Risks on Hydroxychloroquine Based on 2021 ACR Consensus: A Quality Improvement Project
Cristine Kuzhuppilly Arcilla¹, Gabriel Kirsch², Gurjit Kaeley³ and Myint Thway⁴, ¹University of Florida Jacksonville, Jacksonville, FL, ²University of Florida - Jacksonville, Jacksonville, FL, ³UF COM-J, Ponte Vedra Beach, FL, ⁴UF Jacksonville, ponte vedra, FL
Background/Purpose: In 2017, FDA approved warnings regarding fatal cardiac effects such as cardiomyopathy, torsades de pointes, and QTc prolongation related to both acute and chronic…
Abstract Number: 1370 • ACR Convergence 2025
Impact of Six-Month Monitoring Compared to Three-Month Monitoring of Labs for Methotrexate Toxicity
Spencer Simko¹, Sohini Mukherjee², Ray Zhang², Puneet Bajaj³ and Bonnie Bermas⁴, ¹University of Texas Southwestern, Dallas, TX, ²University of Texas Southwestern, Dallas, ³UT Southwestern Medical Center, Dallas, TX, ⁴UTSouthwestern.edu, Dallas, TX
Background/Purpose: Current rheumatology treatment guidelines recommend lab monitoring for methotrexate toxicity at three-month intervals for established patients. We sought to evaluate whether monitoring labs at…
Abstract Number: 1041 • ACR Convergence 2025
Associated Factors And Direct Cost Analysis Of Dose Reduction And Discontinuation Of Biological Therapies In Rheumatoid Arthritis And Spondyloarthritis: Findings From A Colombian Cohort Within The Framework Of An Integrated Management Model
Edwin Jauregui¹, Deisy Restrepo², Belcy Garzon², Alexis Atuesta², Nestor Correa², Jessica Barrera² and Andrea Rubio², ¹Riesgo de fractura S.A, Bogotá, Colombia, ²Riesgo de fractura S.A, Bogotá, Colombia
Background/Purpose: Dose reduction of biologic therapy (BT) in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) has been increasingly implemented in recent years, in accordance…
Abstract Number: 1039 • ACR Convergence 2025
CAR-T Therapy in Rheumatoid Arthritis: A Health Systems Analysis of Cost and Global Equity
Asrith Reddy Gandu¹ and Kolluri Prathyusha², ¹Davao medical school foundation, Hyderabad, India, ²University of delaware, Newark, DE
Background/Purpose: Refractory rheumatoid arthritis (RA) affects 30–40% of patients with limited therapeutic options and high disability burdens. Although CAR‑T therapy has been transformative in oncology…
Abstract Number: 0829 • ACR Convergence 2025
Multi-Center Use of an Online Case-Based Simulation to Evaluate Medical Trainee Use of Diagnostic Imaging and Lab Tests to Correctly Diagnose MSK Complaints
James McCarthey¹, Kyla Driest², erin frank¹, Allayne Stephans¹, Stacey Tarvin³ and Angela Robinson⁴, ¹Rainbow Babies and Children's Hospital, Cleveland, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Riley Hospital for Children at Indiana University, Indianapolis, IN, ⁴Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Our goal is to teach medical trainees high value care concepts and musculoskeletal (MSK) disease states and then implement online case-based simulations to evaluate…
Abstract Number: 0787 • ACR Convergence 2025
The Cost-effectiveness of Physical Therapy for Patients with Meniscal Tear and Osteoarthritis
Samantha Chin¹, Sasha Aronson¹, Jamie Collins¹, Faith Selzer¹, Ying Heidi Yang¹, Leslie Bisson², Antonia Chen³, Morgan Jones⁴, Clare Norton¹, Karen Smith¹, Kurt Spindler⁵, Jeffrey Katz⁶ and Elena Losina⁷, ¹Brigham and Women's Hospital, Boston, MA, ²University of Buffalo, Buffalo, ³Brigham and Women's Hospital, Newton, MA, ⁴Mass General Brigham, Boston, ⁵Cleveland Clinic, Cleveland, ⁶Brigham and Women's Hospital, Brookline, MA, ⁷BWH, Boston, MA
Background/Purpose: Based on several RCTs comparing outcomes of arthroscopic partial meniscectomy (APM) to non-operative management in persons with meniscal tears and OA, physical therapy (PT)…
Abstract Number: 0761 • ACR Convergence 2025
Fast-Track Clinics Improve Visual Outcomes in Giant Cell Arteritis: A Meta-Analysis
Tiago Beirão¹, Catarina Rua¹, Catarina Silva¹, Mariana Patela¹, Romana Vieira¹, Joana Abelha-aleixo¹, Patrícia Pinto¹, Flávio Costa¹, Ana Sofia Pinto¹, Diogo Fonseca¹, Tiago Meirinhos¹, Ajexandro Souto² and Taciana Videira¹, ¹Unidade Local de Saude Gaia e Espinho, Porto, Portugal, ²Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain
Background/Purpose: Giant Cell Arteritis (GCA) is a chronic, inflammatory condition, primary affecting the medium and larger arteries, usually in patients older than 50 years. It…
Abstract Number: 0519 • ACR Convergence 2025
A Multi-criterion Feature Integration Framework for Accurate Diagnosis of Primary Sjögren’s Syndrome Using Routine Laboratory Tests: A Multicentre, Retrospective Cohort study
Shu Liu¹, Guanhao Wu¹, Mengge Pan¹, Qi Sun², Jingchen Gao¹, Xianming Long³, Chaogui Tang⁴, Xinran Yuan¹ and Lingyun Sun¹, ¹Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China (People's Republic), ²Department of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong, China, Nantong, China (People's Republic), ³The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China (People's Republic), ⁴The Affiliated Huaian First People’s Hospital of Nanjing Medical University, Huai’an First People’s Hospital, Nanjing Medical University, Huaian, China (People's Republic)
Background/Purpose: Primary Sjögren's syndrome (pSS) is a prevalent systemic autoimmune disorder. However, the early and accurate diagnosis of pSS remains challenging due to its non-specific…
Abstract Number: 0447 • ACR Convergence 2025
Foot-pressure distribution method for detection of foot joint arthritis in patients with rheumatic diseases
Hayagrivas Manicka Bharathkumar¹, Emani Srinija Reddy¹, Bhaskar Pandey², Suryansh Saini¹, Sangeet Rathi¹, Saransh Verma¹, Chinmay Prakash Swami², Deepak Joshi² and Ranjan Gupta¹, ¹All India Institute of Medical Sciences (AIIMS), New Delhi, Delhi, Delhi, India, ²Indian Institute of Technology (IIT), Delhi, Delhi, Delhi, India
Background/Purpose: Rheumatoid arthritis (RA) and Seronegative Spondyloarthritis (SSA), the most common types of inflammatory arthritis, have significant ankle and foot joint involvement. However, these joints…
Abstract Number: 0195 • ACR Convergence 2025
Utility of Repeat ANA Testing
Michael Luggen¹ and Sila Mateo Faxas², ¹University of Cincinnati College of Medicine, Cincinnati, OH, ²Good Samaritan Hospital, Cincinnati, OH
Background/Purpose: The ANA by immunofluorescence is a sensitive screening test for most systemic auto-immune rheumatic diseases (SARDs). A negative result is oftentimes sufficient to exclude…
Abstract Number: 2271 • ACR Convergence 2025
Assessing the Real-World Impact of Earlier Initiation of Adalimumab vs. Conventional Synthetic DMARDs on Healthcare Resource Utilization in Patients with Rheumatoid Arthritis in Europe
Daniel Aletaha¹, Dr. Carmen Bremer², Jack Milligan³, Zichun Cao⁴, Rachael Meadows³ and Xenofon Baraliakos⁵, ¹Medical University Vienna, Wien, Austria, ²Sandoz International GmbH, Holzkirchen, Germany, ³Adelphi Real World, Macclesfield, United Kingdom, ⁴Sandoz Incorporated, Princeton, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Early use of targeted therapy (TT), such as anti-tumor necrosis factor (anti-TNF) biologics, show improved outcomes for RA1, but costs often limit access. Biosimilars,…
Abstract Number: 0146 • ACR Convergence 2024
Enhancing Pre-Biologic Response Modifier Screening for Coccidioidomycosis in Endemic Regions
Bashar Tanous¹, SRIKAR SAMA², Nidaa Rasheed³ and Candice Reyes⁴, ¹UCSF Fresno, Fresno, ²University of California San Francisco Fresno, Fresno, CA, ³UCSF Fresno, Fresno, CA, ⁴VACCHCS, Fresno, CA
Background/Purpose: Biologic response modifiers (BRMs), also known as "biologics," have become essential tools in treating various chronic inflammatory conditions. However, the immunosuppression caused by these agents…
Abstract Number: 0212 • ACR Convergence 2024
Costs of Hospitalization in Patients with SLE: An Analysis of the National Inpatient Sample
Brandon Blau¹, Kelsey Gripp¹, Catherine MacLean² and Bella Mehta², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with significant health care utilization, medical costs, and increased risk of hospitalization. We aimed to characterize the reasons…
Abstract Number: 0274 • ACR Convergence 2024
Cost-effectiveness of Low Dose Colchicine Prophylaxis When Starting Allopurinol Using the “Start-Low Go-Slow” Approach for Gout
Yana Pryymachenko¹, Ross Wilson¹, Haxby Abbott¹, Nicola Dalbeth² and Lisa Stamp³, ¹University of Otago, Dunedin, New Zealand, ²University of Auckland, Auckland, New Zealand, ³University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: To investigate the cost-effectiveness of low-dose colchicine prophylaxis for reducing gout flares when starting allopurinol using the “start-low go-slow” approach.Methods: This was a pre-planned…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].